3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate | 887511-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate
• 英文别名: 3-O-ethyl 4-O-methyl 2-iodothiophene-3,4-dicarboxylate
• CAS: 887511-47-9
• 化学式: C₉H₉IO₄S
• 分子量: 340.139
• InChiKey: KIGZWCWAAQODPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 24.0h， 以80.5%的产率得到2-iodothiophene-3,4-dicarboxylic acid
  参考文献：
  名称：

  高性能双极发光介聚物中的分子量工程

  摘要：

  具有高溶解度、无结构缺陷且批次间差异可忽略不计的介聚物为有机光电子学开辟了一条新途径。有机发光晶体管结合了有机发光二极管和有机场效应晶体管的功能。然而，在一种共轭聚合物中，电荷传输能力和发光强度是矛盾的。在此，获得了三种具有噻吩并吡咯二酮-苯并噻二唑重复单元（meso-TBTF）的低分子量内聚体。内聚体显示出强烈的固态发射和高双极性载流子迁移率。内消旋 TBTF 的分子量可以通过聚合温度进行调节。内聚体的光致发光量子产率 (PLQY) 在溶液中约为 50%，在固态时约为 10%。

  DOI：

  10.1002/anie.202105036
• 作为产物：
  描述：

  2-氨基-3,4-噻吩羧酸-3-乙基-4-甲酯 在 盐酸 、 potassium iodide 、 sodium nitrite 作用下， 以 水 为溶剂， 以47%的产率得到3-ethyl 4-methyl 2-iodothiophene-3,4-dicarboxylate
  参考文献：
  名称：

  噻吩并[3,4- c ]吡咯-4,6-二酮基聚合物的低成本合成及物理表征

  摘要：

  提出了改进的噻吩并[3,4- c ]吡咯-4,6-二酮（TPD）单体的合成方法，包括Gewald噻吩环形成，Sandmeyer型反应以及与胺的纯净缩合反应。与传统方法相比，该协议可以更快，更便宜，更有效地制备TPD装置。此外，通过直接杂芳基聚合（DHAP）程序合成了一系列带有各种烷基链的TPD均聚物和假均聚物。紫外可见吸收和粉末X射线衍射测量揭示了支链与直链烷基链之比与聚合物的光电特性及其在固态状态下的堆积之间的关系。

  DOI：

  10.1021/jo301512e

文献信息

• Structural Insight into Aggregation and Orientation of TPD-Based Conjugated Polymers for Efficient Charge-Transporting Properties
  作者：Dae-Hee Lim、Yeon-Ju Kim、Yeong-A Kim、Kyoungtae Hwang、Jong-Jin Park、Dong-Yu Kim

  DOI：10.1021/acs.chemmater.8b04605

  日期：2019.7.9

  In this study, we obtained a new structural insight into the charge-transporting properties in TPD-based polymers that cannot be solely explained in terms of the type of orientation. We synthesized two types of copolymers comprising mono-TPD or bis-TPD as the accepting unit. Although the planarity and energy levels are similar with the mono-TPD unit, the aggregation state is quite different, and the X-aggregation tendency seems to be stronger when the bis-TPD unit is incorporated. In the case of TPD1, an effective π–π orbital overlap is found to originate from the H-aggregates, and 3D charge transport pathways are formed with a bimodal orientation of edge-on and face-on, resulting in an efficient charge transportation (1.84 cm2·V–1·s–1 of hole and 0.31 cm2·V–1·s–1 of electron). In contrast, despite the well-aligned edge-on orientation of TPD2, it exhibited a relatively very low mobility and splitted emission characteristics in photoluminescence spectra because of the tilted intermolecular stacking pattern with an X-shape (0.015 cm2·V–1·s–1 for hole and 0.16 cm2·V–1·s–1 for electron). An overall characterization of the semiconducting polymers was performed, and it was found that the type of aggregation in the final thin films, such as H- or X-aggregation, is indeed important and perhaps more important than the orientation to obtain polymers with a high charge carrier mobility.

  在本研究中，我们对基于TPD的聚合物中的电荷传输性质获得了新的结构洞察，这些性质不能仅从取向类型来解释。我们合成了两种类型的共聚物，分别包含单TPD或双TPD作为接受单元。尽管单TPD单元的平面性和能级相似，但其聚集状态有显著差异，且当引入双TPD单元时，X型聚集趋势似乎更强。在TPD1情况下，有效的π-π轨道重叠源自H型聚集，形成了三维电荷传输路径，具有边缘-顶面和顶面-顶面的双峰取向，实现了高效的电荷传输（空穴迁移率为1.84 cm²·V⁻¹·s⁻¹，电子迁移率为0.31 cm²·V⁻¹·s⁻¹）。相比之下，尽管TPD2具有良好的边缘-顶面取向，但由于倾斜的分子间堆积模式呈X形（空穴迁移率为0.015 cm²·V⁻¹·s⁻¹，电子迁移率为0.16 cm²·V⁻¹·s⁻¹），其表现出相对较低的迁移率和光致发光光谱中的分裂发射特性。对半导体聚合物进行了全面的表征，发现最终薄膜中的聚集类型，如H型或X型聚集，确实非常重要，甚至可能比取向更重要，以获得具有高电荷载流子迁移率的聚合物。
• COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
  申请人：BioTheryX, Inc.

  公开号：US20180170948A1

  公开（公告）日：2018-06-21

  The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

  本发明提供了调节蛋白功能的化合物，以恢复蛋白稳态，包括细胞因子、CK1α、GSPT1、艾奥洛斯和/或伊卡洛斯活性和细胞间粘附。该发明提供了一种调节蛋白介导的疾病的方法，如细胞因子介导的疾病、障碍、状况或反应。提供了包括与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防与蛋白相关的疾病、障碍或状况的方法，包括与细胞因子相关的疾病、障碍和状况，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
• Synthesis and Characterization of 5-Octylthieno[3,4-<i>c</i>]pyrrole-4,6-dione Derivatives As New Monomers for Conjugated Copolymers
  作者：Philippe Berrouard、François Grenier、Jean-Rémi Pouliot、Eric Gagnon、Christian Tessier、Mario Leclerc

  DOI：10.1021/ol1027514

  日期：2011.1.7

  An efficient route for the synthesis of 1-iodo-5-octyl-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione as a key intermediate to build new electron-deficient monomers and related conjugated polymers is reported. Along these lines, two new low bandgap copolymers were synthesized from Stille or Suzuki coupling. These polymers were characterized and their properties compared to those of analogous conjugated polymers

  合成1-iodo-5-octyl-4 H -thieno [3,4- c ]吡咯-4,6（5 H）-dione作为构建新型电子缺陷单体的关键中间体的有效途径及相关方法报道了共轭聚合物。沿着这些思路，从Stille或Suzuki偶联反应中合成了两种新的低带隙共聚物。与类似的共轭聚合物相比，对这些聚合物进行了表征，并确定了它们的性能。
• Compounds targeting proteins, compositions, methods, and uses thereof
  申请人：BioTheryX, Inc.

  公开号：US10040804B2

  公开（公告）日：2018-08-07

  The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

  本发明提供了调节蛋白质功能的化合物，以恢复蛋白质的平衡，包括细胞因子、CK1α、GSPT1、aiolos 和/或 ikaros 活性以及细胞-细胞粘附性。本发明提供了调节蛋白质介导的疾病，如细胞因子介导的疾病、失调、病症或反应的方法。本发明提供了组合物，包括与其他细胞因子和炎症介质的组合物。提供了治疗、改善或预防与蛋白质相关的疾病、失调或病症的方法，例如与细胞因子相关的疾病、失调和病症，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
• THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
  申请人：Biotheryx, Inc.

  公开号：EP3559005A1

  公开（公告）日：2019-10-30